



Glucagon Manufacturing in PLI Scheme

Source: BS

- Recently, the government decided to manufacture a **Glucagon-like peptide receptor agonist (GLP-1RA)** drug in **India** under the **Production Linked Incentive (PLI) scheme** from 2026.
- **GLP-1RA** is a class of **anti-diabetic drugs** which are also used for **weight loss**.
- Apart from GLP-1RA, investors are planning to make other drugs like **Ozempic (for diabetes)**, and **Wegovy (for obesity)** at the site and the **PLI scheme** will provide manufacturing avenues in India.
- The **PLI scheme** is an ambitious central scheme to scale up **domestic manufacturing capability**, accompanied by **higher import substitution** and **employment generation**.
- Launched in March **2020**, the scheme at present covers **14 sectors**.
- Under the scheme, **Domestic and Foreign companies** receive financial rewards for manufacturing in India, based on a percentage of their revenue over up to five years.

Read more: [Production Linked Incentive Scheme](#)

PDF Refernece URL: <https://www.drishtias.com/printpdf/glucagon-manufacturing-in-pli-scheme>



DRISHTI
The Vision